COVID-19 and Heart: From Clinical Features to Pharmacological Implications.
Vincenzo RussoRoberta BottinoAndreina CarboneAnna RagoAndrea Antonio PapaPaolo GolinoGerardo NigroPublished in: Journal of clinical medicine (2020)
A highly pathogenic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak which has spread rapidly from China to other countries in the world, causing a pandemic with alarming morbidity and mortality. The emerging epidemiological data about COVID-19 patients suggest an association between cardiovascular diseases (CVD) and SARS-CoV-2 infection, in term of clinical features at hospital admission and prognosis for disease severity. The aim of our review is to describe the cardiological features of COVID-19 patients at admission, the acute cardiac presentation, the clinical outcome for patients with underlying CVD and the pharmacological implications for disease management.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- sars cov
- emergency department
- cardiovascular disease
- endothelial cells
- liver failure
- heart failure
- preterm infants
- left ventricular
- healthcare
- electronic health record
- respiratory failure
- induced pluripotent stem cells
- atrial fibrillation
- drug induced
- metabolic syndrome
- acute care
- hepatitis b virus
- pluripotent stem cells